February 11, 2005 |
Pfizer Inc. and Microsoft Corp. are teaming up to fight the slew of spam e-mails hawking Viagra that invade consumers' computers. The companies said they had filed a total of 17 lawsuits against defendants involved in the sale and distribution of the erectile dysfunction drug. The Redmond, Wash., software giant has targeted spammers before, but this is the first time the company has joined forces with a non-technology firm.
December 3, 2006 |
Pfizer Inc. said it had cut off all clinical trials and development for a cholesterol drug because of an unexpected number of deaths and cardiovascular problems in patients who used it. The drug maker said an independent board monitoring a study for torcetrapib, a drug that raises good cholesterol, recommended that the work end. Pfizer is asking clinical investigators conducting trials to warn patients to stop taking the drug.
September 2, 2006 |
A federal judge upheld the validity of Pfizer Inc.'s U.S. patent covering the active ingredient in Norvasc, the world's top-selling blood-pressure medication. The ruling in Durham, N.C., blocks Dutch generic drug maker Synthon from selling a cheaper copy of Norvasc until at least September 2007, when the patent expires.
October 6, 2006 |
Pfizer Inc. must defend a lawsuit in which people claim its diabetes drug Rezulin damaged their livers. A federal appeals court in New York reinstated a case dismissed last year in a lower court. The appeals court said New York-based Pfizer wasn't shielded from the suit by state law in Michigan, as the lower-court judge had found. Plaintiffs in the case live in Michigan. Pfizer did not immediately comment.
December 29, 2006 |
Pfizer Inc. won a trademark case blocking drug makers in China from copying its Viagra erectile dysfunction pills' blue diamond shape. A Beijing court ordered the three companies to pay a $38,000 fine to Pfizer, stop producing the blue, diamond-shaped pills -- which didn't contain the active ingredient in Viagra -- and print an apology in a Chinese legal newspaper, Pfizer said.
August 18, 2007 |
Pfizer Inc. has lost a preliminary bid to gain reissuance of one of the U.S. patents protecting its Lipitor cholesterol medicine. Should the ruling stand, Pfizer would face U.S. generic competition to Lipitor, the world's top-selling drug, in March 2010 rather than in June 2011. Pfizer's sales for Lipitor were $12.9 billion last year, including $7.8 billion in the U.S.
December 18, 2002 |
Cadbury Schweppes agreed to buy Pfizer Inc.'s Adams candy unit for $4.2 billion in cash to become the world's second-largest chewing-gum maker by adding brands such as Trident and Dentyne. The British maker of Dr. Pepper and Dairy Milk chocolate, in its biggest acquisition, is gaining a business with $1.9 billion in sales in 2001. Adams returns Cadbury to the U.S. confectionery market after a break of 14 years. Shares of London-based Cadbury fell $1.01 to $24.94.
October 29, 2005 |
Pfizer Inc. said U.S. regulators extended its review period for Exubera, an inhaled insulin treatment that could serve as an alternative to needles for 4 million American diabetics. The Food and Drug Administration needs as long as three months to look at additional data provided by the companies, New York-based Pfizer said. Pfizer developed Exubera, the first treatment of its type, with Nektar Therapeutics of San Carlos, Calif., and Sanofi-Aventis of Paris.